EpiRepress
Dosing And Dispensing Made Easy With The Launch Of Virbacs Canine Epilepsy Treatment, EpiRepress
7 years ago 
1684 views
Virbac has launched EpiRepress, a new treatment for epilepsy in dogs which aims to make dosing and dispensing easy and accurate for practice staff and for owners.
EpiRepress contains tried and trusted phenobarbital, the only ingredient licensed to treat both idiopathic and structural epilepsy, and which provides clinical improvement in 85% of cases.1 The product is offered in the conventional 60mg tablet strength, which can be split into two or into four to enable dosing to be tailored to the needs of an individual patient.
EpiRepress is the first epilepsy treatment to be offered in easy-to-dispense boxes of 30 tablets, removing the need for the practice team to count out tablets from larger pots – a process which can now be done without the need to handle individual tablets. According to Virbac, the smaller box size also makes the purchase price more manageable for clients.
An innovative range of resources for practices and owners has been created by Virbac to support the use of EpiRepress. It includes a comprehensive Epilepsy Diary, packed with useful questions and tips; a handy folder to keep the Diary and extra materials in one safe place; and a diagnostic and treatment poster for the practices to use complete with differentials.
Commenting on the launch of EpiRepress, Virbac Product Manager Sarah Dixon MRCVS said: “The prevalence of canine epilepsy means that most practices are seeing at least one case a week.2 Phenobarbital is the mainstay treatment for canine epilepsy and, in developing our product, we wanted to offer practices and owners an easier, more accurate and more cost-effective solution.1 EpiRepress, with its divisible 60mg tablets and smaller box size, is the result and we are delighted to be able to launch it.
“We are focused on supporting practices and owners with compliance so have also developed a novel practice support package for EpiRepress. It offers the latest guidance to both vet practices and pet owners on the diagnosis, treatment and management of this challenging disease.”
Founded by a veterinary surgeon, Virbac is dedicated to supporting the veterinary profession through the development of innovative products and services, which help animals to lead longer, healthier lives. One of the largest independent veterinary pharmaceutical companies in the world, its wide product portfolio includes many market-leading and award-winning products for large and small animals.
Date: 1 February 2017
Podell, M., Volk, H. A., Berendt, M., Loscher, W., Munana, K., Patterson, E. E., & Platt, S. R. (2016). 2015 ACVIM Small Animal Consensus Statement on Seizure Management in Dogs, Journal of Veterinary Internal Medicine, 30, 477-490.
IVETF (2015). International Veterinary Epilepsy Task Force Consensus Reports. Available at: www.biomedcentral.com/bmcvetres/series/IVETF_consensus_reports.
EpiRepress© 60 mg tablets for dogs. Tablets can be divided into halves and quarters and contain phenobarbital for oral use in dogs. Legal category: POM-V Schedule 3. Refer to the product packaging and leaflets for information about side effects, precautions, warnings and contra-indications. Advice should be sought from the medicine prescriber. Use medicines responsibly. www.noah.co.uk/responsible.
Issued by/further information from:
Rebecca George, George PR
Tel: 01449 737281/07974 161108: E-mail: [email protected]
More from Virbac Animal Health
- Virbac launches the Multimin Focus Guide, an online resource for vets and farmers
- Virbac Adds Pyoderm™ to Their New and Improved Eco-Friendly Shampoo Range
- Virbac Announces Significant Licence Change for Zoletil™
- Virbac Presents New WSAVA Reproduction Guidelines Webinar
- Bovigen Scour – Scour protection that lasts
